000			02041 a2200517 4500
005			20250515225912.0
264		0	_c20101020
008			201010s 0 0 eng d
022			_a0008-543X
024	7		_a10.1002/cncr.25280 _2doi
040			_aNLM _beng _cNLM
100	1		_aMorschhauser, Franck
245	0	0	_aEfficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS). _h[electronic resource]
260			_bCancer _cSep 2010
300			_a4299-308 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Murine-Derived
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aDrug Administration Schedule
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aLymphoma, Follicular _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMitoxantrone _xadministration & dosage
650	0	4	_aNeoplasms, Second Primary _xepidemiology
650	0	4	_aRecurrence
650	0	4	_aRituximab
650	0	4	_aTumor Burden
650	0	4	_aVidarabine _xadministration & dosage
700	1		_aMounier, Nicolas
700	1		_aSebban, Catherine
700	1		_aBrice, Pauline
700	1		_aSolal-Celigny, Phillippe
700	1		_aTilly, Herve
700	1		_aFeugier, Pierre
700	1		_aFermé, Christophe
700	1		_aCopin, Marie Christine
700	1		_aLamy, Thierry
773	0		_tCancer _gvol. 116 _gno. 18 _gp. 4299-308
856	4	0	_uhttps://doi.org/10.1002/cncr.25280 _zAvailable from publisher's website
999			_c19899237 _d19899237